medicationPrescription only (US)Approved by the FDA as Strattera for ADHD in children, adolescents, and adults, and carries a boxed warning about suicidal ideation in pediatric patientsNot a stimulant and not federally scheduled, unlike most other ADHD medications
AtomoxetineBenefits, Dosage & Interactions
Also known as: Strattera
Atomoxetine, marketed under the brand name Strattera, is a medication primarily used in the treatment of attention-deficit hyperactivity disorder (ADHD). Unlike many other ADHD medications, atomoxetine is a non-stimulant. It is typically taken in the morning. The reported plasma half-life is about 5 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 4 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
4 human randomized trials and regulatory approval on file.
Plasma half-life
~5 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Adult ADHD trials titrated atomoxetine up to roughly 80–120 mg/day, most often reached via a starting dose near 40 mg/day[1][2][3][4]
- Frequency
- Once-daily dosing was studied directly in two of the cited trials; the original registration trials used twice-daily dosing[1][2][3][4]
Reported for Atomoxetine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Atomoxetine entry is written from. Each number matches an inline marker above.
- [1]Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesMichelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ · Biological Psychiatry · 2003 · Peer-reviewed · PMID 12547466
- [2]Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trialYoung JL, Sarkis E, Qiao M, Wietecha L · Clinical Neuropharmacology · 2011 · Peer-reviewed · PMID 21406998
- [3]Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trialAdler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K · Journal of Clinical Psychopharmacology · 2009 · Peer-reviewed · PMID 19142107
- [4]Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorderLee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW · Asia-Pacific Psychiatry · 2014 · Peer-reviewed · PMID 25345739
How to track Atomoxetine doses
Tracking Atomoxetine well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Atomoxetine with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Atomoxetine through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 5 h, effects and timing shifts show up over days rather than instantly. Review Atomoxetine alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Atomoxetine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Atomoxetine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Atomoxetine, marketed under the brand name Strattera, is a medication primarily used in the treatment of attention-deficit hyperactivity disorder (ADHD). Unlike many other ADHD medications, atomoxetine is a non-stimulant. It is approved for use in children, adolescents, and adults. Its action involves affecting specific neurochemicals in the brain, leading to improvements in attention span, hyperactivity, and impulsivity. As a non-controlled substance, it may be an option for individuals who do not respond well to stimulants or experience significant side effects from them, or for those with co-occurring conditions that preclude stimulant use. (Source: DrugBank, MedlinePlus)
What does the research say about Atomoxetine?
Tap a section to expand.
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI). It works by blocking the reabsorption of norepinephrine, a neurotransmitter, back into the nerve cells. This action increases the concentration of norepinephrine in the synaptic cleft, the space between nerve cells in the brain. Norepinephrine plays a crucial role in attention, focus, impulsivity, and activity levels. By increasing its availability, atomoxetine helps to improve communication between brain cells involved in these functions, thereby alleviating the core symptoms of ADHD. The therapeutic effects of atomoxetine typically develop gradually over several weeks rather than immediately, as is common with stimulant medications. (Source: DrugBank, NIH)
Source for this section: Sources for How does Atomoxetine work?: Jumps to this entry in the sources and references list at the end of the page.
- **ADHD Symptom Management:** Atomoxetine helps to reduce key symptoms of ADHD, including inattention, hyperactivity, and impulsivity. This can lead to improved academic performance, social interactions, and daily functioning.
- **Non-Stimulant Option:** For individuals who cannot tolerate or do not respond to stimulant medications, atomoxetine provides an alternative. It does not carry the same risk of abuse or dependence as stimulants, making it a suitable choice for some patient populations.
- **24-Hour Coverage:** Due to its steady plasma concentrations, atomoxetine provides symptom control throughout the day and into the evening, which can be beneficial for consistent symptom management. (Source: FDA label, Mayo Clinic)
Numerous randomized controlled trials and meta-analyses support the efficacy of atomoxetine in treating ADHD across different age groups. For instance, studies published in peer-reviewed journals have demonstrated its effectiveness in reducing ADHD symptom severity scores compared to placebo in pediatric, adolescent, and adult populations. Long-term studies have also indicated sustained benefits. Research has also explored its use in individuals with comorbid conditions, such as anxiety disorders, where stimulants might be less suitable. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved atomoxetine for the treatment of ADHD based on extensive clinical trial data. (Source: Cochrane, FDA label, EMA SmPC)
Common side effects associated with atomoxetine include nausea, dry mouth, insomnia, decreased appetite, constipation, dizziness, and fatigue. In children and adolescents, stomach upset and decreased appetite are frequently reported. Less common but more serious side effects can include cardiovascular events (e.g., increased heart rate and blood pressure), liver problems, and suicidal ideation, particularly in children and adolescents during the initial weeks of treatment or dose changes. Priapism (a prolonged erection) is a rare but serious side effect. Any concerning or persistent side effects should be reported to a healthcare provider immediately. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Atomoxetine carries a Boxed Warning regarding an increased risk of suicidal ideation in children and adolescents. Patients, their families, and caregivers should be vigilant for the emergence or worsening of depression, suicidal thoughts, or unusual changes in behavior. Cardiovascular effects, including increased blood pressure and heart rate, warrant careful monitoring, especially in individuals with pre-existing heart conditions or hypertension. Liver injury, though rare, has been reported, and patients should be monitored for signs such as dark urine, jaundice, or upper right quadrant tenderness. Before starting atomoxetine, a thorough medical history, including family history of heart disease and mental health conditions, should be taken. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Atomoxetine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should not be used in patients with a history of pheochromocytoma or other serious cardiovascular disorders that could be worsened by increases in blood pressure or heart rate. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serious, potentially fatal reactions, including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes, including extreme agitation progressing to delirium and coma. Atomoxetine should not be initiated within 14 days of discontinuing an MAOI, and MAOIs should not be initiated within 14 days of discontinuing atomoxetine. Patients with narrow-angle glaucoma should also avoid atomoxetine. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
- **Monoamine Oxidase Inhibitors (MAOIs):** Concurrent use or use within 14 days of discontinuing an MAOI is strictly contraindicated due to the risk of severe and potentially fatal adverse reactions, including hypertensive crisis and serotonin syndrome. (Source: FDA label)
- **CYP2D6 Inhibitors:** Medications that strongly inhibit the CYP2D6 enzyme (e.g., fluoxetine, paroxetine, quinidine) can significantly increase plasma concentrations of atomoxetine, potentially increasing the risk of side effects. Dose adjustments of atomoxetine may be necessary. (Source: DrugBank)
- **Vasopressor Agents or Agents That Increase Blood Pressure:** Atomoxetine can increase blood pressure and heart rate. Caution is advised when co-administering with other medications that have similar effects, as this could exacerbate cardiovascular risks. (Source: FDA label)
- **Beta-Agonists:** Co-administration with beta-agonists can potentially increase cardiovascular effects. (Source: EMA SmPC)
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Atomoxetine is typically taken once or twice daily, with or without food. Given its half-life of approximately 5 hours (though some individuals may have a longer half-life due to genetic variations in CYP2D6 metabolism), a once-daily dose is often taken in the morning to provide sustained symptom control throughout the day. If a twice-daily regimen is prescribed, the doses are usually spaced to maintain consistent levels. The specific dose and administration schedule are user-directed and must be set by a licensed clinician. (Source: FDA label, DrugBank)
Source for this section: Sources for When should you take Atomoxetine?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Atomoxetine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Atomoxetine
Atomoxetine is a medication. It is also known as Strattera. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Atomoxetine is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Atomoxetine, it is typically taken in the morning and its approximate half-life is 5 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Atomoxetine carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Atomoxetine comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Atomoxetine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Atomoxetine with no sign-up.
There is no single answer for Atomoxetine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Atomoxetine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 5 hours is why protocols often split Atomoxetine across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Atomoxetine clears quickly (plasma half-life around 5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Atomoxetine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 54840(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/54840
Verify at
Publisher search links for Atomoxetine. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Atomoxetine?
Plain-text summary, safe to quote verbatim:
Atomoxetine, marketed under the brand name Strattera, is a medication primarily used in the treatment of attention-deficit hyperactivity disorder (ADHD). Unlike many other ADHD medications, atomoxetine is a non-stimulant. It is typically taken in the morning. The reported plasma half-life is about 5 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/atomoxetine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Atomoxetine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/atomoxetine
What compounds are similar to Atomoxetine?
Others in the medication category or studied for the same goals.